

Section I. (Amendment of the Claims)

Please cancel claims 15-30, amend claims 1-7 and 9-14, as set out in the following listing of claims 1-30 of the application.


1. (currently amended) A method of combating movement disorder in a patient experiencing or susceptible to same who is being treated with dopaminergic medication, anticonvulsant medication or antianxiolytic medication, said method comprising by administering to the patient an effective amount of a neurotransmission modulating composition comprising a 5HT antagonist and/or α_1 antagonist, with the proviso that the neurotransmission modulating composition does not comprise yohimbine, cyproheptadine, or 5 MDOT mirtazapine.
2. (currently amended) The method of claim 1, wherein ~~the composition comprises a 5HT antagonist~~ said patient is being treated with dopaminergic medication.
3. (currently amended) The method of claim 1 ~~2~~, wherein ~~the composition comprises a 5HT antagonist including at least one of 5HT2 antagonists and 5HT3 antagonists~~ said dopaminergic medication comprises a dopa agonist.
4. (currently amended) The method of claim 1 ~~2~~, wherein ~~the composition comprises an α_1 antagonist~~ said dopaminergic medication comprises medication selected from the group consisting of (i) levodopa, (ii) levodopa in combination with carbidopa, and (iii) ropirinoles.

BEST AVAILABLE COPY

5. (currently amended) The method of claim 1, wherein ~~the composition comprises a compound that is both a 5HT antagonist and an α_2 antagonist~~ said patient is being treated with anticonvulsant medication.
6. (currently amended) The method of claim 1, wherein said movement disorder comprises ~~dyskinesia~~ bradykinesia.
7. (currently amended) The method of claim 1, wherein said movement disorder comprises ~~a condition selected from the group consisting of tremors, akathisia, asterixis, athetosis, chorea/athetosis, tics, chorea/choreaform movements, dystonias, spasticity, restless legs syndrome, hyperkinetic movement disorders, hemiballismus, myoclonus, and tardive dyskinesia~~ resting tremor.
8. (original) The method of claim 1, wherein said movement disorder comprises tremor.
9. (currently amended) The method of claim 1, wherein said movement disorder comprises ~~a peripheral neuropathy-associated tremor~~ action tremor.
10. (currently amended) The method of claim ~~1~~ 5, wherein said ~~movement disorder~~ comprises at least one tremor condition selected from the group consisting of Parkinsonian tremors, rubral tremors, post-traumatic tremors, drug induced tremors, cerebellar tremors, and Tourette syndromal tremors anticonvulsant medication comprises primidone.
11. (currently amended) The method of claim 1, wherein said ~~movement disorder derives from neurological impairment of the basal ganglia~~ patient is being treated with anxiolytic medication.

12. (currently amended) The method of claim 1 11, wherein said ~~movement disorder~~ comprises a disorder selected from the group consisting of Parkinsonian tremor, action tremor and levodopa-induced dyskinesias anxiolytic medication comprises propranolol.
13. (currently amended) The method of claim 1 11, wherein said ~~composition comprises at least one compound selected from the group consisting of:~~

(a) ~~—tetraacyclic compounds of the formula:~~



~~or a salt thereof, wherein~~

~~A represents a pyridine ring or a halogen substituted pyridine ring,~~

~~R₁ represents hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, halogen, OH, SH or CF₃,~~

~~R₂ represents hydrogen or a lower alkyl or aralkyl group, and~~


~~n and m may each be 1, 2 or 3 with the proviso that the sum of m and n must be 2, 3 or 4;~~

(b) ~~—imidazolines;~~

(c) ~~—ergot alkaloids; and~~

(d) ~~indolealkylamine alkaloids~~ anxiolytic medication comprises an SSRI.

14. (currently amended) The method of claim ~~1~~ 11, wherein said ~~composition comprises at least one tetracyclic compound of the formula:~~



~~or a salt thereof, wherein~~

~~A represents a pyridine ring or a halogen-substituted pyridine ring,~~

~~R₁ represents hydrogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkylthio, halogen, OH, SH or CF₃;~~

~~R₂ represents hydrogen or a lower alkyl or aralkyl group, and~~

~~n and m may each be 1, 2 or 3 with the proviso that the sum of m and n must be 2, 3 or 4~~

anxiolytic medication comprises a benzodiazapine.

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.